YM155, a selective survivin inhibitor, reverses chronic hypoxic pulmonary hypertension in rats via upregulating voltage-gated potassium channels. (August 2015)

• Record Type: Journal Article
• Authors: Fan, Zaiwen; Liu, Bo; Zhang, Shuai; Liu, Huiguo; Li, Yang; Wang, Dong; Liu, Ying; Li, Jian; Wang, Ning; Liu, Yi; Zhang, Bo
• Is Part Of: Clinical and experimental hypertension. Volume 37:Number 5(2015)
• Page Start: 381
• Page End: 387
• Publication Date: 2015-08
• Subjects: Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• Languages: English
• ISSNs: 1064-1963

Abstract

<abstract> <title>Abstract</title> <p>To test the hypothesis that chronic hypoxic pulmonary hypertension (CH-PH) is associated with increased survivin and decreased voltage-gated potassium (K_V) channels expression in pulmonary arteries, rats were randomized as: normoxia (N); normoxia + YM155, survivin suppressor (NY); hypoxia (H); hypoxia + YM155 (HY). HY group had significantly reduced pulmonary arterial pressure, right ventricular weight and right ventricular hypertrophy compared with H group. Survivin mRNA and protein were detected in pulmonary arteries of rats with CH-PH, but not rats without CH-PH. YM155 downregulated survivin protein and mRNA. K_V channel expression and activity were upregulated after YM155 treatment. Survivin may play a role in the pathogenesis of CH-PH.</p> </abstract>